84-3363-69　LYVE-1 (Lymphatic Vessel Endothelial Hyaluronic Acid Receptor, LYVE1, CRSBP1, Extracellular Link Domain Containing 1, Hyaluronic Acid Receptor, HAR, Lymphatic Endothelium Specific Hyaluronan Receptor, Lymphatic Vessel Endothelial Hyaluronan Receptor 1, XLKD1) (HRP) 100ul　L9375-03H-HRP

特徴

• LYVE1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall.
• The deduced amino acid sequence of LYVE1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily.
• Like CD44, the LYVE1 molecule binds both soluble and immobilized HA.
• However, unlike CD44, the LYVE1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels.
• Hence, LYVE1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
• LYVE1 may function in lymphatic hyaluronan transport.
• Additionally, LYVE1 has a role in tumor metastasis.
• Applications: Suitable for use in Immunohistochemistry.
• Other applications not tested.
• Recommended Dilution:Immunohistochemistry: 1:1000Optimal dilutions to be determined by the researcher.
• Positive Control:Ovarian cancer tissue.
• Storage and Stability:Store product at 4°C if to be used immediately within two weeks.
• For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C.
• Aliquots are stable at -20°C for 12 months after receipt.
• Dilute required amount only prior to immediate use.
• Further dilutions can be made in assay buffer.
• Note: Sodium azide is a potent inhibitor of peroxidase and should not be added to HRP conjugates.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Note: Applications are based on unconjugated antibody.